Penobscot Investment Management Company Inc. Boosts Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Penobscot Investment Management Company Inc. grew its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 2.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,450 shares of the company’s stock after buying an additional 450 shares during the quarter. Penobscot Investment Management Company Inc. owned 0.48% of Invesco Biotechnology & Genome ETF worth $1,294,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. LPL Financial LLC increased its position in Invesco Biotechnology & Genome ETF by 1.7% during the 4th quarter. LPL Financial LLC now owns 92,105 shares of the company’s stock worth $6,128,000 after purchasing an additional 1,503 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Invesco Biotechnology & Genome ETF by 16.9% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,002 shares of the company’s stock worth $1,730,000 after purchasing an additional 3,764 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the fourth quarter worth about $1,256,000. Massachusetts Wealth Management raised its position in shares of Invesco Biotechnology & Genome ETF by 1.3% in the fourth quarter. Massachusetts Wealth Management now owns 18,414 shares of the company’s stock valued at $1,225,000 after buying an additional 230 shares during the last quarter. Finally, IHT Wealth Management LLC lifted its stake in shares of Invesco Biotechnology & Genome ETF by 14.7% during the third quarter. IHT Wealth Management LLC now owns 12,124 shares of the company’s stock valued at $847,000 after buying an additional 1,550 shares during the period.

Invesco Biotechnology & Genome ETF Stock Down 2.1 %

Shares of Invesco Biotechnology & Genome ETF stock opened at $64.89 on Thursday. Invesco Biotechnology & Genome ETF has a fifty-two week low of $59.32 and a fifty-two week high of $72.84. The business’s fifty day moving average is $67.36 and its two-hundred day moving average is $68.46. The firm has a market cap of $235.55 million, a PE ratio of 23.00 and a beta of 0.80.

Invesco Biotechnology & Genome ETF Increases Dividend

The business also recently disclosed a dividend, which will be paid on Friday, March 28th. Stockholders of record on Monday, March 24th will be paid a dividend of $0.0341 per share. The ex-dividend date is Monday, March 24th. This is a boost from Invesco Biotechnology & Genome ETF’s previous dividend of $0.01.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.